News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eurand Partners with Prestige Brands, Inc. on Sleep-eze(R) eze-melts


11/19/2010 12:53:11 PM

November 19, 2010 -- YARDLEY, Pa. – Eurand, a global specialty pharmaceutical company, has recently partnered with Prestige Brands Holdings, Inc. on a new orally disintegrating tablet (ODT) formulation of its over-the- counter (OTC) sleep-aid, Sleep-eze®. Sleep-eze® eze-melts, which contain 25 mg of diphenhydramine hydrochloride, was developed and licensed by Eurand using its AdvaTab® and Microcaps® taste-masking technologies. Sleep-eze® eze-melts, an OTC sleep-aid, was successfully launched in August 2010 and is now available in leading Canadian mass merchandiser, drug and food retailers. Eurand supplies the Sleep-eze® eze-melts product exclusively for Prestige Brands. The product is manufactured at Eurand’s U.S. facility in Vandalia, Ohio.

Prestige Brands Holdings, Inc. markets and sells well-recognized, brand name consumer over-the- counter healthcare and household cleaning products throughout the U.S., Canada and certain international markets. The Company operates in niche segments within these categories in which the strength of the brand names, the established retail distribution network, a low cost operating model, and an experienced management team are keys to success.

AdvaTab® Product Portfolio

Eurand’s AdvaTab technology can also be applied to products in the prescription (Rx) category, most notably with the 2009 GlaxoSmithKline launch of LAMICTAL® ODT™ (lamotrigine) Orally Disintegrating Tablets, indicated for epilepsy as adjunctive therapy in patients =2 years of age; epilepsy as monotherapy in patients =16 years of age; and bipolar disorder in patients =18 years of age. Lamictal ODT is available in 25 mg, 50 mg, 100 mg and 200 mg strengths as a fruity-flavored tablet that disintegrates in the mouth and can be taken with or without food or water (www.lamictal.com)

Continuing OTC product development, Eurand is offering licensing opportunities for AdvaTab®

Acetaminophen (also known as paracetamol), incorporating Eurand’s expertise to mask the notably bitter- tasting drug. AdvaTab® Acetaminophen is an immediate-release product that is formulated in a range of dosing strengths for both pediatric and adult consumers (80 mg – 500 mg). The convenient, easy-to- swallow dosage form can be taken with or without water and disintegrates within 30 seconds in compliance with FDA guidelines. The acetaminophen formulation complies with the USP monograph; therefore, scale-up to launch could be completed for a partner in as little as six months (conditions apply).

About AdvaTab®

Eurand’s AdvaTab® technology utilizes proprietary granulation and tabletting processes to provide an orally disintegrating tablet with superior mouth-feel attributes. When combined with Eurand’s Microcaps® taste-masking technology, AdvaTab ODTs are one of the leading orally disintegrating tablet systems available to the pharmaceutical industry today. Key features of AdvaTab include: excellent mouth-feel; tablets that can be packaged in bottles or blisters; rapid disintegration in the oral cavity; ability to incorporate microencapsulated drug particles; and the capacity to incorporate larger drug doses than conventional ODT technologies.

To obtain a free AdvaTab prototype from a licensing representative, visit the company’s website at www.eurand.com/contact.html.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste- masking/orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.

If you’d like to learn more about this topic or to schedule a meeting with Eurand, please contact Troy Harmon at +1 267-759-9340 or email Troy at troy.harmon@eurand.com.

You can also contact Eurand via our website at: http://www.eurand.com/contact.html


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES